S&P 500   4,575.82 (+0.18%)
DOW   36,049.55 (+0.27%)
QQQ   387.94 (-0.23%)
AAPL   190.79 (+0.44%)
MSFT   372.08 (-1.80%)
META   322.66 (-1.37%)
GOOGL   131.02 (-1.14%)
AMZN   146.52 (+0.29%)
TSLA   236.76 (-1.38%)
NVDA   467.96 (+0.06%)
NIO   7.12 (-2.06%)
BABA   73.00 (-2.51%)
AMD   120.38 (-0.64%)
T   16.64 (+0.42%)
F   10.47 (+2.05%)
MU   76.14 (+0.03%)
CGC   0.58 (+2.68%)
GE   123.02 (+1.00%)
DIS   91.83 (-0.93%)
AMC   6.80 (+2.26%)
PFE   29.13 (-4.40%)
PYPL   58.51 (+1.56%)
XOM   103.95 (+1.18%)
S&P 500   4,575.82 (+0.18%)
DOW   36,049.55 (+0.27%)
QQQ   387.94 (-0.23%)
AAPL   190.79 (+0.44%)
MSFT   372.08 (-1.80%)
META   322.66 (-1.37%)
GOOGL   131.02 (-1.14%)
AMZN   146.52 (+0.29%)
TSLA   236.76 (-1.38%)
NVDA   467.96 (+0.06%)
NIO   7.12 (-2.06%)
BABA   73.00 (-2.51%)
AMD   120.38 (-0.64%)
T   16.64 (+0.42%)
F   10.47 (+2.05%)
MU   76.14 (+0.03%)
CGC   0.58 (+2.68%)
GE   123.02 (+1.00%)
DIS   91.83 (-0.93%)
AMC   6.80 (+2.26%)
PFE   29.13 (-4.40%)
PYPL   58.51 (+1.56%)
XOM   103.95 (+1.18%)
S&P 500   4,575.82 (+0.18%)
DOW   36,049.55 (+0.27%)
QQQ   387.94 (-0.23%)
AAPL   190.79 (+0.44%)
MSFT   372.08 (-1.80%)
META   322.66 (-1.37%)
GOOGL   131.02 (-1.14%)
AMZN   146.52 (+0.29%)
TSLA   236.76 (-1.38%)
NVDA   467.96 (+0.06%)
NIO   7.12 (-2.06%)
BABA   73.00 (-2.51%)
AMD   120.38 (-0.64%)
T   16.64 (+0.42%)
F   10.47 (+2.05%)
MU   76.14 (+0.03%)
CGC   0.58 (+2.68%)
GE   123.02 (+1.00%)
DIS   91.83 (-0.93%)
AMC   6.80 (+2.26%)
PFE   29.13 (-4.40%)
PYPL   58.51 (+1.56%)
XOM   103.95 (+1.18%)
S&P 500   4,575.82 (+0.18%)
DOW   36,049.55 (+0.27%)
QQQ   387.94 (-0.23%)
AAPL   190.79 (+0.44%)
MSFT   372.08 (-1.80%)
META   322.66 (-1.37%)
GOOGL   131.02 (-1.14%)
AMZN   146.52 (+0.29%)
TSLA   236.76 (-1.38%)
NVDA   467.96 (+0.06%)
NIO   7.12 (-2.06%)
BABA   73.00 (-2.51%)
AMD   120.38 (-0.64%)
T   16.64 (+0.42%)
F   10.47 (+2.05%)
MU   76.14 (+0.03%)
CGC   0.58 (+2.68%)
GE   123.02 (+1.00%)
DIS   91.83 (-0.93%)
AMC   6.80 (+2.26%)
PFE   29.13 (-4.40%)
PYPL   58.51 (+1.56%)
XOM   103.95 (+1.18%)

PURE Bioscience Stock Price, News & Analysis (OTCMKTS:PURE)

$0.12
0.00 (0.00%)
(As of 11/30/2023 ET)
Compare
Today's Range
$0.11
$0.12
50-Day Range
$0.08
$0.12
52-Week Range
$0.07
$0.20
Volume
25,787 shs
Average Volume
20,759 shs
Market Capitalization
$13.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

PURE stock logo

About PURE Bioscience Stock (OTCMKTS:PURE)

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.

PURE Stock Price History

PURE Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
PURE Bioscience Reports Fiscal 2023 Financial Results
PURE Bioscience Reports Fiscal 2023 Financial Results
Michigan launches $20M talent campaign
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Layoffs hit Morrisville firm as it scales back operations
PURE - PURE Bioscience, Inc.
PURE Bioscience Stock (OTC:PURE), Dividends
Why Is NightHawk Biosciences (NHWK) Stock Up 26% Today?
See More Headlines
Receive PURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PURE Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/30/2023
Today
12/01/2023
Next Earnings (Estimated)
12/12/2023
Fiscal Year End
7/31/2024

Industry, Sector and Symbol

Industry
Miscellaneous chemical products
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:PURE
Employees
11
Year Founded
1992

Profitability

Net Income
$-3,960,000.00
Net Margins
-219.09%
Pretax Margin
-211.03%

Debt

Sales & Book Value

Annual Sales
$1.87 million

Miscellaneous

Free Float
64,407,000
Market Cap
$13.20 million
Optionable
Not Optionable
Beta
0.10

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Robert F. Bartlett (Age 78)
    President, CEO & Director
    Comp: $129.8k
  • Mr. Mark Stuart Elliott (Age 48)
    VP of Finance and Principal Financial & Accounting Officer
    Comp: $180k
  • Mr. Thomas Richard Myers (Age 71)
    Executive VP of Technology & Development and Director
    Comp: $200k














PURE Stock Analysis - Frequently Asked Questions

How have PURE shares performed in 2023?

PURE Bioscience's stock was trading at $0.0848 at the start of the year. Since then, PURE stock has increased by 39.2% and is now trading at $0.1180.
View the best growth stocks for 2023 here
.

Are investors shorting PURE Bioscience?

PURE Bioscience saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 900 shares, an increase of 125.0% from the October 31st total of 400 shares. Based on an average trading volume of 49,700 shares, the days-to-cover ratio is currently 0.0 days.
View PURE Bioscience's Short Interest
.

When is PURE Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, December 12th 2023.
View our PURE earnings forecast
.

How were PURE Bioscience's earnings last quarter?

PURE Bioscience, Inc. (OTCMKTS:PURE) issued its earnings results on Monday, October, 30th. The company reported ($0.03) earnings per share for the quarter. The firm earned $1.47 million during the quarter. PURE Bioscience had a negative trailing twelve-month return on equity of 364.82% and a negative net margin of 219.09%.

What other stocks do shareholders of PURE Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PURE Bioscience investors own include NVIDIA (NVDA), Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), Riot Platforms (RIOT), Enphase Energy (ENPH), Mastercard (MA), Main Street Capital (MAIN), Twilio (TWLO) and

How do I buy shares of PURE Bioscience?

Shares of PURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:PURE) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -